Feasibility and acceptability of transcutaneous tibial nerve stimulation for the treatment of bladder storage symptoms among people with multiple sclerosis

Hawra B Al Dandan, Rose Galvin, Katie Robinson, Doreen McClurg, Susan Coote, Hawra B Al Dandan, Rose Galvin, Katie Robinson, Doreen McClurg, Susan Coote

Abstract

Background: Neurogenic lower urinary tract dysfunction is an abnormality in the presence of underlying neurologic disease. A recent systematic review and meta-analysis demonstrated that storage phase symptoms are the predominant symptoms among people with multiple sclerosis (PwMS). Transcutaneous tibial nerve stimulation (TTNS) is a non-invasive treatment for bladder storage symptoms; however, the potential efficacy of stimulation among PwMS is based on a small number of studies with the absence of high-quality evidence. The aim of this study was to evaluate the feasibility, acceptability, and safety of TTNS in PwMS using an affordable transcutaneous electrical nerve stimulation (TENS) unit.

Methods: A total of 23 participants with MS enrolled in the study. The primary outcomes included recruitment/retention rate, completion of the outcomes and the intervention, adherence to the protocol, adverse events, and acceptability of the intervention. The primary outcomes were assessed using diaries and a satisfaction questionnaire. The secondary outcomes included changes in urinary symptoms and quality of life assessed using a set of validated outcome measures including a 3-day bladder diary, PPIUS, ICIQ-OAB, and KHQ at baseline and post-intervention.

Results: Twenty participants completed the study. Three participants (13.04%) withdrew. All 20 participants completed the 6-week intervention and all the outcome measures (100%), with no reported adverse events. Participants were satisfied and found the unit acceptable. Three-day bladder diary showed changes in urinary frequency from a daily median of 10 times to 8 times and daily median urgency changed from 6 times at baseline to 2 times post-intervention. PPIUS showed changes in daily median sever urgency from 3 points (IQR=4) to 1 point (IQR=1) post-intervention. ICIQ-OAB total scores changed from 8 points (IQR=2.25) to 4 points (IQR=2.5) post-intervention. Median and mean scores of KHQ showed a clinical meaningful change of QoL in part-two and part-three of the questionnaire.

Conclusions: TTNS is feasible, safe, and acceptable for PwMS. Changes of urinary symptoms scores and QoL post-intervention suggested improvements. Future implications need to consider the treatment protocol including frequency of treatment sessions, duration of treatment, and the electrical stimulation parameters as well as the outcome measures followed in the current study for the implementation of the future pilot RCT.

Trial registration: ClinicalTrials.gov NCT04528784 . Registered on 27 August 2020. https://register.

Clinicaltrials: gov/prs/app/action/LoginUser?ts=1&cx=-jg9qo4 .

Keywords: Electrical nerve stimulation; Neurogenic lower urinary tract dysfunction; Neuromodulation; Quality of life questionnaire; Tibial nerve.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flow diagram of MS participants

References

    1. Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD) Neurourol Urodyn. 2018;37(3):1152–1161. doi: 10.1002/nau.23397.
    1. Patel DP, Elliott SP, Stoffel JT, Brant WO, Hotaling JM, Myers JB. Patient reported outcomes measures in neurogenic bladder and bowel: A systematic review of the current literature. Neurourol Urodyn. 2016;35(1):8–14. doi: 10.1002/nau.22673.
    1. Peter TD, Peter MM. Neurogenic Bladder. Adv Urol. 2012;2012:2012.
    1. Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14(7):720–732. doi: 10.1016/S1474-4422(15)00070-8.
    1. Al Dandan HB, Coote S, McClurg D. Prevalence of Lower Urinary Tract Symptoms in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. Int J MS Care. 2020;22(2):91–99. doi: 10.7224/1537-2073.2019-030.
    1. Di Benedetto P, Delneri C, Biasutti E, Bragadin LM, Giorgini T. Vesicourethral dysfunction in multiple sclerosis. Initial assessment based on lower urinary tract symptoms and their pathophysiology. Neurol Sci. 2008;29(4):348–351. doi: 10.1007/s10072-008-1041-z.
    1. Nortvedt MW, Riise T, Myhr KM, Landtblom AM, Bakke A, Nyland HI. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler. 2001;7(4):231–235. doi: 10.1177/135245850100700404.
    1. Khan F, Pallant JF, Shea TL, Whishaw M. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil. 2009;31(19):1567–1576. doi: 10.1080/09638280802639566.
    1. Vitkova M, Rosenberger J, Krokavcova M, Szilasiova J, Gdovinova Z, Groothoff JW, et al. Health-related quality of life in multiple sclerosis patients with bladder, bowel and sexual dysfunction. Disabil Rehabil. 2014;36(12):987–992. doi: 10.3109/09638288.2013.825332.
    1. Browne C, Salmon N, Kehoe M. Bladder dysfunction and quality of life for people with multiple sclerosis. Disabil Rehabil. 2015;37(25):2350–2358. doi: 10.3109/09638288.2015.1027007.
    1. Spencer N. Urinary incontinence and unemployment in people with multiple sclerosis. Int J MS Care. 2007;9(4):143–147. doi: 10.7224/1537-2073-9.4.143.
    1. Al Dandan HB, Galvin R, McClurg D, Coote S, Robinson K. Management strategies for neurogenic lower urinary tract dysfunction: a qualitative study of the experiences of people with multiple sclerosis and healthcare professionals. Disabil Rehabil. 2021;1–11.
    1. Jezernik S, Craggs M, Grill WM, Creasey G, Rijkhoff NJ. Electrical stimulation for the treatment of bladder dysfunction: current status and future possibilities. Neurol Res. 2002;24(5):413–430. doi: 10.1179/016164102101200294.
    1. Zecca C, Panicari L, Disanto G, Maino P, Singh A, Digesu GA, et al. Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis. Int Urogynecol J. 2016;27(4):521–527. doi: 10.1007/s00192-015-2814-6.
    1. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud. 2016;2:64. doi: 10.1186/s40814-016-0105-8.
    1. Al Dandan HB, Galvin R, Robinson K, McClurg D, Coote S. Transcutaneous tibial nerve stimulation for the treatment of bladder storage symptoms in people with multiple sclerosis: protocol of a single-arm feasibility study. HRB Open Res. 2020;3.
    1. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589–595. doi: 10.1191/1352458504ms1085oa.
    1. Robertson V, Ward A, Low J, Reed A, & MCSP D. Electrotherapy explained: principles and practice. Elsevier Health Sciences. 2006.
    1. Groen J, Bosch JL. Neuromodulation techniques in the treatment of the overactive bladder. BJU Int. 2001;87(8):723–731. doi: 10.1046/j.1464-410x.2001.02219.x.
    1. Castel-Lacanal E. Sites of electrical stimulation used in neurology. Ann Phys Rehabil Med. 2015;58(4):201–207. doi: 10.1016/j.rehab.2015.05.004.
    1. de Seze M, Raibaut P, Gallien P, Even-Schneider A, Denys P, Bonniaud V, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(3):306–311. doi: 10.1002/nau.20958.
    1. Vargas Luna JL, Krenn M, Mayr W, Cortes Ramirez JA. Optimization of Interphase Intervals to Enhance the Evoked Muscular Responses of Transcutaneous Neuromuscular Electrical Stimulation. Artif Organs. 2017;41(12):1145–1152. doi: 10.1111/aor.12921.
    1. Monteiro ÉS, de Carvalho LBC, Fukujima MM, Lora MI, Do Prado GF. Electrical Stimulation of the Posterior Tibialis Nerve Improves Symptoms of Poststroke Neurogenic Overactive Bladder in Men: A Randomized Controlled Trial. Urology. 2014;84(3):509–514. doi: 10.1016/j.urology.2014.05.031.
    1. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharmacy Rep. 2019;92(2):117.
    1. Zappavigna C, Carr LK. Validated Questionnaires for the Evaluation of Urinary Incontinence—Which, When and Why? Curr Bladder Dysfunction Rep. 2015;10(2):138–142. doi: 10.1007/s11884-015-0290-y.
    1. Abrams P, Andersson K-E, Apostolidis A, Birder L, Bliss D, Brubaker L, et al. 6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. Neurourol Urodyn. 2018;37(7):2271–2272. doi: 10.1002/nau.23551.
    1. Abrams P, Avery K, Gardener N, Donovan J, Board IA. The international consultation on incontinence modular questionnaire: www. iciq. net. J Urol. 2006;175(3):1063–1066. doi: 10.1016/S0022-5347(05)00348-4.
    1. Nambiar A, Lucas M. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) Neurourol Urodyn. 2014;33(Suppl 3):S21–S25. doi: 10.1002/nau.22631.
    1. Jimenez-Cidre MA, Lopez-Fando L, Esteban-Fuertes M, Prieto-Chaparro L, Llorens-Martinez FJ, Salinas-Casado J, et al. The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women. Neurourol Urodyn. 2015;34(2):128–132. doi: 10.1002/nau.22530.
    1. Notte SM, Marshall TS, Lee M, Hakimi Z, Odeyemi I, Chen W-H, et al. Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder. BMC Urol. 2012;12(1):26. doi: 10.1186/1471-2490-12-26.
    1. Pat Ray R, Andreas MP, Gary JO, Con JK. Multinational Study of Reliability and Validity of the King's Health Questionnaire in Patients with Overactive Bladder. Qual Life Res. 2003;12(4):427–442. doi: 10.1023/A:1023422208910.
    1. Okamura K, Nojiri Y, Osuga Y. Reliability and validity of the Kings Health Questionnaire for lower urinary tract symptoms in both genders. BJU Int. 2009;103(12):1673–1678. doi: 10.1111/j.1464-410X.2008.08335.x.
    1. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10(1):1–10. doi: 10.1186/1471-2288-10-1.
    1. Hebbar S, Pandey H, Chawla A. Understanding King’s Health Questionnaire (KHQ) in assessment of female urinary incontinence. Int J Res Med Sci. 2015;3(3):531–538. doi: 10.5455/2320-6012.ijrms20150301.
    1. Lewis M, Bromley K, Sutton CJ, McCray G, Myers HL, Lancaster GA. Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back! Pilot Feasibility Stud. 2021;7(1):1–14. doi: 10.1186/s40814-021-00770-x.
    1. Zolnierek KBH, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47(8):826–834. doi: 10.1097/MLR.0b013e31819a5acc.
    1. Venegas M, Carrasco B, Casas-Cordero R. Factors influencing long-term adherence to pelvic floor exercises in women with urinary incontinence. Neurourol Urodyn. 2018;37(3):1120–1127. doi: 10.1002/nau.23432.
    1. Dumoulin C, Hay-Smith J, Frawley H, McClurg D, Alewijnse D, Bo K, et al. 2014 consensus statement on improving pelvic floor muscle training adherence: International Continence Society 2011 State-of-the-Science Seminar. Neurourol Urodyn. 2015;34(7):600–605. doi: 10.1002/nau.22796.
    1. Sacomori C, Zomkowski K, Dos Passos PI, Cardoso FL, Sperandio FF. Adherence and effectiveness of a single instruction of pelvic floor exercises: a randomized clinical trial. Int Urogynecol J. 2020;31(5):951–959. doi: 10.1007/s00192-019-04032-6.
    1. Tudor KI, Seth JH, Liechti MD, Ochulor J, Gonzales G, Haslam C, et al. Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder. Clin Auto Res. 2020;30(1):61–7.
    1. Abrams P, Cardozo L, Wagg A, Wein A. Incontinence 6th edition ICI-ICS. Bristol: International Continence Society edn; 2017.
    1. Booth J, Connelly L, Dickson S, Duncan F, Lawrence M. The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: a systematic review. Neurourol Urodyn. 2018;37(2):528–541. doi: 10.1002/nau.23351.
    1. Valles-Antuna C, Perez-Haro ML, Gonzalez-Ruiz de LC, Quintas-Blanco A, Tamargo-Diaz EM, Garcia-Rodriguez J, et al. Transcutaneous stimulation of the posterior tibial nerve for treating refractory urge incontinence of idiopathic and neurogenic origin. Actas Urol Esp. 2017;41(7):465–470. doi: 10.1016/j.acuro.2017.01.009.
    1. Welk B, McKibbon M. A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. Can Urol Assoc Jl. 2020;14(7):E297.
    1. Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World J Urol. 2014;32(1):179–184. doi: 10.1007/s00345-013-1112-5.
    1. Seth JH, Gonzales G, Haslam C, Pakzad M, Vashisht A, Sahai A, et al. Feasibility of using a novel non-invasive ambulatory tibial nerve stimulation device for the home-based treatment of overactive bladder symptoms. Transl Androl Urol. 2018;7(6):912. doi: 10.21037/tau.2018.09.12.
    1. Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH. How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder. BJOG Int J Obstet Gynaecol. 2004;111(6):605–612. doi: 10.1111/j.1471-0528.2004.00129.x.
    1. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–1216. doi: 10.1002/nau.22251.
    1. Schneider MP, Gross T, Bachmann LM, Blok BF, Castro-Diaz D, Del Popolo G, et al. Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review. Eur Urol. 2015;68(5):859–867. doi: 10.1016/j.eururo.2015.07.001.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe